Formulation and in vivo evaluation of orally disintegrating tablets of clozapine/hydroxypropyl-β-cyclodextrin inclusion complexes

AAPS PharmSciTech

Volumn 14, Issue 2, 2013, Pages 854-860

  Zeng, Fan ^a   Wang, Ling ^a   Zhang, Wenjing ^a   Shi, Kejing ^a   Zong, Li ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

bioavailability; clozapine; hydroxypropyl cyclodextrin; inclusion complexes; orally disintegrating tablets

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CLOZAPINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; COMPLEX FORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SCREENING; DRUG SOLUBILITY; EVAPORATION; EXPERIMENTAL RABBIT; FIRST PASS EFFECT; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; ORALLY DISINTEGRATING TABLET; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TABLET; TABLET COMPRESSION; TABLET DISINTEGRATION; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY POWDER DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIPSYCHOTIC AGENTS; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CLOZAPINE; CRYSTALLOGRAPHY, X-RAY; DRUG CARRIERS; MALE; POWDER DIFFRACTION; RABBITS; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TABLETS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84879112536     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-013-9973-x     Document Type: Article

References (27)

1. Sweetman SC. Martindale: the complete drug reference. 36th ed. London: Pharmaceutical Press; 2009. p. 768-71.
2. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58:265-78.
3. Gerald KM. AHFS drug information. Bethesda: American Society of Health-System Pharmacists Press; 2004. p. 2273-85.
4. Seager H. Drug delivery products and the Zydis fast dissolving dosage forms. J Pharm Pharmacol. 1998;50:375-82.
5. Badgujar BP, Mundada AS. The technologies used for developing orally disintegrating tablets: a review. Acta Pharm. 2011;61:117-39.
6. Goel H, Rai P, Rana V, Tiwary AK. Orally disintegrating systems: innovations in formulation and technology. Recent Pat Drug Deliv Formul. 2008;2:258-74.
7. Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem Rev. 1998;98:1743-54.
8. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev. 1998;98:2045-76.
9. Misiuk W, Zalewska M. Investigation of inclusion complex of trazodone hydrochloride with hydroxypropyl-β-cyclodextrin. Carbohydr Polym. 2009;77:482-8.
10. Gould S, Scott RC. 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): a toxicology review. Food Chem Toxicol. 2005;43:1451-9.
11. Higuchi T, Connors KA. Phase solubility techniques. Adv Anal Chem Instrum. 1965;4:117-212.
12. Yadav VR, Suresh S, Devi K, Yadav S. Effect of cyclodextrin complexation of curcumin on its solubility and antiangiogenic and anti-inflammatory activity in rat colitis model. AAPS PharmSciTech. 2009;10:752-62.
13. Jain SK, Shukla M, Shrivastava V. Development and in vitro evaluation of ibuprofen mouth dissolving tablets using solid dispersion technique. Chem Pharm Bull. 2010;58:1037-42.
14. Rajitha K, Shravan KY, Adukondalu D, Ramesh G, Madhusudan Y. Formulation and evaluation of orally disintegrating tablets of buspirone. Int J Pharm Sci Nanotechnol. 2009;1:372-4.
15. US Food and Drug Administration. In vivo bioequivalence guidances. Pharmacopeial Forum. 1993;19:6501-8.
16. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85:1017-25.
17. Zornoza A, Martín C, Sánchez M, Vélaz I, Piquer A. Inclusion complexation of glisentide with α-, β- and γ-cyclodextrins. Int J Pharm. 1998;169:239-44.
18. Fernandes CM, Teresa Vieira M, Veiga FJ. Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds. Eur J Pharm Sci. 2002;15:79-88.
19. Carrier RL, Miller LA, Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J Control Release. 2007;123:78-99.
20. Cirri M, Righi MF, Maestrelli F, Mura P, Valleri M. Development of glyburide fast-dissolving tablets based on the combined use of cyclodextrins and polymers. Drug Dev Ind Pharm. 2009;35:73-82.
21. Cirri M, Rangoni C, Maestrelli F, Corti G, Mura P. Development of fast-dissolving tablets of flurbiprofen-cyclodextrin complexes. Drug Dev Ind Pharm. 2005;31:697-707.
22. Williams RO, Mahaguna V, Sriwongjanya M. Characterization of an inclusion complex of cholesterol and hydroxypropyl-beta-cyclodextrin. Eur J Pharm Biopharm. 1998;46:355-60.
23. Veiga F, Fernandes C, Maincent P. Influence of the preparation method on the physicochemical properties of tolbutamide/cyclodextrin binary systems. Drug Dev Ind Pharm. 2001;27:523-32.
24. Dali MM, Moench PA, Mathias NR, Stetsko PI, Heran CL, Smith RL. A rabbit model for sublingual drug delivery: comparison with human pharmacokinetic studies of propranolol, verapamil and captopril. J Pharm Sci. 2006;95:37-44.
25. Odou P, Barthelemy C, Chatelier D, Luyckx M, Brunet C, Dine T, et al. Pharmacokinetics of midazolam: comparison of sublingual and intravenous routes in rabbit. Eur J Drug Metab Pharmacokinet. 1999;24:1-7.
26. Nie S, Fan X, Peng Y, Yang X, Wang C, Pan W. In vitro and in vivo studies on the complexes of vinpocetine with hydroxypropyl-β-cyclodextrin. Arch Pharm Res. 2006;30:991-1001.
27. Bekers O, Uijtendaal EV, Beijnen JH, Buit A, Under-berg WJM. Cyclodextrins in the pharmaceutical field. Drug Dev Ind Pharm. 1991;17:1503-49.